In Brief: FDA Ophthalmic Drugs Subcommittee
Executive Summary
FDA Ophthalmic Drugs Subcommittee: Panel will review Chiron's Vitrasert ganciclovir ophthalmic implant for cytomegalovirus retinitis (NDA 20-569) on Dec. 8. During the afternoon, the subcommittee will review Pharmacia & Upjohn's Xalatan (latanoprost, NDA 20-597) for reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The meeting will begin at 8:30 a.m., Holiday Inn, Silver Spring, Md...